Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease

Coronary Artery Disease

Volumn 25, Issue 6, 2014, Pages 498-504

  Liu, Cong Lin ^a   Shen, De Liang ^a   Zhu, Kui ^a   Tang, Jun Nan ^a   Wang, Xiao Fang ^a   Zhang, Li ^a   Zhang, Jin Ying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 33; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 28; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MMP28 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; VASCULAR LESION; ANGINA, STABLE; ANGINA, UNSTABLE; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; IMMUNOLOGY; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AGED; ANGINA, STABLE; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84905512393     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000117     Document Type: Article

References (30)

1. Spinale FG. Epilysin (matrix metalloproteinase-28) joins the matrix metalloproteinase team on the field of postmyocardial infarction remodeling. Circ Res 2013; 112:579-582.
2. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 2011; 50:331-347.
3. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-490.
4. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008; 52: 2166-2174.
5. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7:827-840.
6. McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010; 185:1222-1229.
7. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117:1538-1549.
8. Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem 2001; 276:10134-10144.
9. Marchenko GN, Strongin AY. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene 2001; 265:87-93.
10. Gharib SA, Johnston LK, Huizar I, Birkland TP, Hanson J, Wang Y, et al. MMP28 promotes macrophage polarization toward M2 cells and augments pulmonary fibrosis. J Leukoc Biol 2014; 95:9-18.
11. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60:1581-1598.
12. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 2013; 61:e179-e347.
13. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. Circulation 1999; 99:2829-2848.
14. Matheeussen V,Waumans Y, Martinet W, Van Goethem S, Van der Veken P, Scharpé S, et al. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 2013; 108:350.
15. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One 2011; 6:e21816.
16. Yang Z, Grinchuk V, Urban JF Jr, Bohl J, Sun R, Notari L, et al. Macrophages as IL-25/IL-33-responsive cells play an important role in the induction of type immunity. PLoS One 2013; 8:e59441.
17. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13:453-461.
18. Ross R, Ross XL, Ghadially H, Lahr T, Schwing J, Knop J, Reske-Kunz AB. Mouse Langerhans cells differentially express an activated T cell attracting CC chemokine. J Invest Dermatol 1999; 113:991-998.
19. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
20. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339-346.
21. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012; 52:89-99.
22. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-490.
23. Miller AM, Liew FY. The IL-33/ST2 pathway - a new therapeutic target in cardiovascular disease. Pharmacol Ther 2011; 131:179-186.
24. Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010; 1803:39-54.
25. Heiskanen TJ, Illman SA, Lohi J, Keski-Oja J, Calabrese N, Bahou W, Cao J. Epilysin (MMP-28) is deposited to the basolateral extracellular matrix of epithelial cells. Matrix Biol 2009; 28:74-83.
26. Pavlaki M, Zucker S, Dufour A, Ramirez TA, Levin D, Voorhees A, et al. Furin functions as a nonproteolytic chaperone for matrix metalloproteinase-28: MMP-28 propeptide sequence requirement. Biochem Res Int 2011; 2011:630319.
27. Ma Y, Halade GV, Zhang J, et al. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res 2013; 112:675-688.
28. Ma Y, Chiao YA, Zhang J, Manicone AM, Jin YF, Lindsey ML. Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal 2012; 18:81-90.
29. Manicone AM, Birkland TP, Lin M, Betsuyaku T, van Rooijen N, Lohi J, et al. Epilysin (MMP-28) restrains early macrophage recruitment in Pseudomonas aeruginosa pneumonia. J Immunol 2009; 182:3866-3876.
30. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183: 6469-6477.